Monograph
J02AX06 - Anidulafungin |
Propably not porphyrinogenic |
PNP |
Important Information
Risk for gastrointestinal adverse events in the form of diarrhoea, vomiting and nausea motivates vigilance against insufficient intake of food, especially of carbohydrate.
Side effects
Very common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are diarrhoea, vomiting and nausea.
Other common side effects are increased levels of alanine aminotransferase and aspartate aminotransferase.
Rationale
Anidulafungin is not a substrate, inducer or inhibitor of CYP enzymes.
Therapeutic characteristics
Anidulafungin is indicated for the treatment of invasive candidiasis in adult non-neutropenic patients.
Metabolism and pharmacokinetics
Anidulafungin is not metabolised in the liver (SPC). In vitro studies showed that the primary biotransformation of anidulafungin is mediated by slow chemical degradation. It is thought that anidulafungin and its degradation products are exclusively eliminated via biliary excretion (Damle 2009).
It is not a clinically relevant substrate, inducer or inhibitor of CYP450 isoenzymes (Damle 2009 and SPC).
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.
Damle BD, Dowell JA et al. Antimicrob Agents Chemother. 2009 Mar;53(3):1149-56. |
19029327 |
| * | Summary of Product Characteristics | |
| 2. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Anidulafungin. Last edition: date not listed.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia© NAPOS 2024